Immutep Announces Final Results In Phase I/II Chemoimmunotherapy Trial In Metastatic
 

Immutep S.A. announced the publication of a clinical research paper showing that its lead product, IMP321, given with first-line paclitaxel achieved clinical benefit in 90 per cent of metastatic breast carcinoma (MBC) patients. Correlations were observed with both the patients' monocyte (i.e...

More...